These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23289540)

  • 1. Allosteric inhibition of VIM metallo-β-lactamases by a camelid nanobody.
    Sohier JS; Laurent C; Chevigné A; Pardon E; Srinivasan V; Wernery U; Lassaux P; Steyaert J; Galleni M
    Biochem J; 2013 Mar; 450(3):477-86. PubMed ID: 23289540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli.
    Oyen D; Wechselberger R; Srinivasan V; Steyaert J; Barlow JN
    Biochim Biophys Acta; 2013 Oct; 1834(10):2147-57. PubMed ID: 23911607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory Potential of Polyclonal Camel Antibodies against New Delhi Metallo-β-lactamase-1 (NDM-1).
    Ben Abderrazek R; Chammam S; Ksouri A; Perilli M; Dhaouadi S; Mdini I; Benlasfar Z; Amicosante G; Bouhaouala-Zahar B; Piccirilli A
    Molecules; 2020 Sep; 25(19):. PubMed ID: 32998307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.
    Cawez F; Mercuri PS; Morales-Yãnez FJ; Maalouf R; Vandevenne M; Kerff F; Guérin V; Mainil J; Thiry D; Saulmont M; Vanderplasschen A; Lafaye P; Aymé G; Bogaerts P; Dumoulin M; Galleni M
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0149922. PubMed ID: 36892280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and computational investigations of VIM-7: insights into the substrate specificity of vim metallo-β-lactamases.
    Borra PS; Leiros HK; Ahmad R; Spencer J; Leiros I; Walsh TR; Sundsfjord A; Samuelsen O
    J Mol Biol; 2011 Aug; 411(1):174-89. PubMed ID: 21645522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamases.
    Hujer AM; Bethel CR; Bonomo RA
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3980-8. PubMed ID: 15388462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases.
    Leiros HK; Edvardsen KS; Bjerga GE; Samuelsen Ø
    FEBS J; 2015 Mar; 282(6):1031-42. PubMed ID: 25601024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camel-Derived Nanobodies as Potent Inhibitors of New Delhi Metallo-β-Lactamase-1 Enzyme.
    Ben Abderrazek R; Hamdi E; Piccirilli A; Dhaouadi S; Muyldermans S; Perilli M; Bouhaouala-Zahar B
    Molecules; 2024 Mar; 29(7):. PubMed ID: 38611711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-beta-lactamases.
    Merino M; Pérez-Llarena FJ; Kerff F; Poza M; Mallo S; Rumbo-Feal S; Beceiro A; Juan C; Oliver A; Bou G
    J Antimicrob Chemother; 2010 Sep; 65(9):1950-4. PubMed ID: 20624761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae.
    Conrath KE; Lauwereys M; Galleni M; Matagne A; Frère JM; Kinne J; Wyns L; Muyldermans S
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2807-12. PubMed ID: 11557473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
    Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
    J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cloning and biochemical characterization of VIM-12, a novel hybrid VIM-1/VIM-2 metallo-beta-lactamase from a Klebsiella pneumoniae clinical isolate, reveal atypical substrate specificity.
    Kontou M; Pournaras S; Kristo I; Ikonomidis A; Maniatis AN; Stathopoulos C
    Biochemistry; 2007 Nov; 46(45):13170-8. PubMed ID: 17944487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.
    Vincke C; Loris R; Saerens D; Martinez-Rodriguez S; Muyldermans S; Conrath K
    J Biol Chem; 2009 Jan; 284(5):3273-3284. PubMed ID: 19010777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant λ bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line.
    Shoae-Hassani A; Mortazavi-Tabatabaei SA; Sharif S; Madadi S; Rezaei-Khaligh H; Verdi J
    Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):75-83. PubMed ID: 23224340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition.
    Oyen D; Srinivasan V; Steyaert J; Barlow JN
    J Mol Biol; 2011 Mar; 407(1):138-48. PubMed ID: 21238460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.
    Kromann-Hansen T; Oldenburg E; Yung KW; Ghassabeh GH; Muyldermans S; Declerck PJ; Huang M; Andreasen PA; Ngo JC
    J Biol Chem; 2016 Jul; 291(29):15156-68. PubMed ID: 27226628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase.
    Castanheira M; Toleman MA; Jones RN; Schmidt FJ; Walsh TR
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4654-61. PubMed ID: 15561840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of type VI secretion by an anti-TssM llama nanobody.
    Nguyen VS; Logger L; Spinelli S; Desmyter A; Le TT; Kellenberger C; Douzi B; Durand E; Roussel A; Cascales E; Cambillau C
    PLoS One; 2015; 10(3):e0122187. PubMed ID: 25811612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs.
    Vincke C; Gutiérrez C; Wernery U; Devoogdt N; Hassanzadeh-Ghassabeh G; Muyldermans S
    Methods Mol Biol; 2012; 907():145-76. PubMed ID: 22907350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.